The report also indicates that, until March 11, 269 cases of embolic or thromboembolic events had been reported on the European Medicines Agency (EMA) EudraVigilance platform, 202 of them were serious. Of the 269 cases, 224 were registered in the United Kingdom and 30 in the European Economic Area.
Most of the registered cases (60%) occurred in women and the majority mean age was 70 years. Of the cases in the European Economic Area (EEA), 14 people had risk factors for the development of thromboembolic events, such as hypertension, thyroid problems, obesity or chronic hepatitis.
Two 269 cases, 45 cases resulted in the death of patients. In the EEA there were seven fatalities, aged between 24 and 60 years.
The EMA indicates that, based on the cases analyzed, no specific risk factors were found associated with age, gender or clinical history of coagulation. It was not possible to link these rare events to the administration of the vaccine, “but it is possible and the investigation will continue”.
This Wednesday, the EMA director said the regulator is investigating 62 cases of blood clots worldwide, 44 of them in the EEA – where 9.2 million people have already received at least one dose of the vaccine, reported the Reuters.
The safety committee report specifies that a time pattern was detected (the events happened after vaccination) and that the most common problem reported was a low level of platelets. The report also indicates that most of the patients were young adult women, but this can also be justified by the fact that this is eventually the group of people with the most AstraZeneca vaccines given.
Get the latest news delivered to your inbox
Follow us on social media networks